Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

Key Points

• Praxis Precision Medicines surged to a new 52-week high of $382.97, up from a $370.68 close, giving the company a market capitalization of roughly $10.79 billion.
• Analyst sentiment remains broadly positive: the stock has a consensus “Buy” rating and a $573.05 price target, while HC Wainwright maintained a Buy rating with a $1,201 target and RBC reaffirmed its Buy rating.
• The company recently beat quarterly EPS expectations, but remains loss-making and faces near-term cash-burn and execution risks. Potential regulatory decisions and late-stage clinical readouts in the second half of 2026 could be important catalysts.

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $382.97 and last traded at $382.97, with a volume of 359778 shares trading hands. The stock had previously closed at $370.68.

Key Headlines Impacting Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $1,201 price target, implying substantial potential upside from current levels. The firm also improved its FY2026 EPS forecast to a loss of $14.09 from a prior loss estimate of $14.49, raised its FY2027 forecast to a loss of $4.24 from $5.33, and increased its projected profitability for FY2028 through FY2030. Its long-term FY2030 EPS estimate rose to $139.61 from $125.74. These revisions reinforce the investment case that Praxis could transition from development-stage losses to significant earnings if its programs succeed. HC Wainwright estimates
• Positive Sentiment: RBC Capital reaffirmed its Buy rating on Praxis, providing additional sell-side support and helping sustain bullish sentiment around the company’s neurological medicine pipeline. RBC Capital Buy rating
• Positive Sentiment: Praxis was identified as one of four biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical readouts. Such events can materially affect valuation, particularly for a high-beta biotechnology stock. Zacks biotech catalysts article
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day short-interest ratio. Because the figures show no measurable short position, the update offers little evidence of either short-covering support or bearish pressure.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $4.15 from $3.86 and continues to project losses through FY2027. This highlights near-term cash-burn and execution risks, despite much stronger projected earnings beginning in FY2028.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PRAX shares. Wedbush dropped their price target on Praxis Precision Medicines from $166.00 to $162.00 and set an "underperform" rating for the company in a research report on Tuesday, June 2nd. The Goldman Sachs Group assumed coverage on Praxis Precision Medicines in a report on Monday, July 13th. They issued a "buy" rating and a $447.00 target price for the company. Needham & Company LLC lifted their price target on Praxis Precision Medicines from $575.00 to $582.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. TD Cowen reissued a "buy" rating on shares of Praxis Precision Medicines in a research report on Tuesday, June 2nd. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $462.00 price objective (up from $449.00) on shares of Praxis Precision Medicines in a report on Friday, August 7th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $573.05.

Praxis Precision Medicines Stock Up 4.2%

The stock has a market cap of $10.79 billion, a price-to-earnings ratio of -29.88 and a beta of 2.78. The business's fifty day moving average is $306.88 and its two-hundred day moving average is $316.49.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, topping the consensus estimate of ($3.67) by $0.80. As a group, sell-side analysts expect that Praxis Precision Medicines, Inc. will post -14.16 earnings per share for the current year.

Insider Buying and Selling at Praxis Precision Medicines

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total value of $3,611,312.00. Following the transaction, the director directly owned 2,337 shares in the company, valued at approximately $727,554.84. This trade represents a 83.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Praxis Precision Medicines

Institutional investors have recently bought and sold shares of the company. NBC Securities Inc. acquired a new stake in shares of Praxis Precision Medicines in the 4th quarter worth approximately $38,000. Parallel Advisors LLC grew its stake in shares of Praxis Precision Medicines by 3,000.0% during the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company's stock valued at $40,000 after buying an additional 120 shares during the period. Danske Bank A S purchased a new position in Praxis Precision Medicines in the fourth quarter valued at approximately $59,000. Tower Research Capital LLC TRC increased its position in shares of Praxis Precision Medicines by 24.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock worth $77,000 after acquiring an additional 359 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in shares of Praxis Precision Medicines by 60.0% in the 4th quarter. Farther Finance Advisors LLC now owns 368 shares of the company's stock valued at $108,000 after acquiring an additional 138 shares during the period. 67.84% of the stock is owned by institutional investors and hedge funds.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source